Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreli, provides an interesting investment opportunity, according to one portfolio manager with an expertise in biotech investing. Michael Tung is co-portfolio manager of Turner Medical Sciences Long/Short Fund, which was the top ranked long/short fund in 2015 according to Morningstar, with a return of nearly 18 percent. Shkreli, you may recall, was indicted on a scheme to defraud Retrophin, a company he founded and previously served as CEO. Despite the legal drama, Tung said there is not a lot of risk in owing the stock. ‘The management team there is excellent,’ said Tung. ‘It’s a very interesting company in that they have several orphan assets, orphan drugs. In addition, right now they also have over $250-million in cash.’ Tung said the company is looking to make acquisitions, and will benefit from the decline in market valuations of potential biotech targets.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
The Best Way for Investors to Position Their Portfolio In a Volatile Market
When the market is volatile, what is the best way to position your portfolio? Real Money's Stephen Guilfoyle has some tips for investors looking to protect themselves.
Kohl's and 2 Other Retail Earnings That Every Investor Should Watch This Week
Feeling overwhelmed as the markets gear up for retail earnings palooza? Action Alerts PLUS senior analyst Jeff Marks is watching three key retail earnings.
These Artworks are More Expensive Than Jeff Koons 'Rabbit'
Jeff Koons 'Rabbit' sold for $91 million - setting new auction record. Let's have a look at the most expensive artworks that have surpassed even that throughout the years.
What Investors Need to Know About Nvidia for the Rest of 2019
Nvidia reported earnings on Thursday, May 16. Action Alerts PLUS research analyst Zev Fima breaks down what investors need to know about the chip stock going into the second half of 2019.
17 Satirical Game of Thrones' Quotes About Investing
Game of Thrones fans now know who sits on the Iron Throne so we're moving on to Wall Street. Watch the video tribute, as we conjured up quotes for TheStreet Columnists.